CASI PHARMACEUTICALS INC (CASI)
KYG1933S1012 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 17.08M | 47.10M | 38.70M | 57.10M | 53.60M | |||
| Marketable Securities | 1.68M | 2.80M | 9.90M | 9.30M | 600.00K | |||
| Receivables | 10.14M | 13.00M | 9.80M | 4.60M | 1.30M | |||
| Inventories | 15.88M | 6.10M | 1.90M | 1.40M | 4.50M | |||
| Other Current Assets | 14.57M | 4.50M | 1.70M | 1.70M | 1.40M | |||
| Total Current Assets | 59.34M | 73.40M | 62.00M | 74.00M | 61.50M | |||
| Non-Current Assets | ||||||||
| PPE Net | 11.63M | 13.20M | 21.80M | 10.80M | 9.70M | |||
| Investments And Advances | 1.69M | 4.40M | 40.10M | 29.40M | 14.00M | |||
| Intangibles | 1.84M | 1.10M | 12.20M | 13.20M | 16.90M | |||
| Other Non-Current Assets | 766.00K | 4.10M | 2.20M | 300.00K | 500.00K | |||
| Total Non-Current Assets | 15.92M | 22.80M | 76.30M | 53.70M | 41.10M | |||
| TOTAL ASSETS | 75.27M | 96.20M | 138.30M | 127.70M | 102.60M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 1.30M | 0.00 | |||
| Accrued Expenses | 12.29M | 11.80M | 8.40M | 3.00M | 2.80M | |||
| Accounts Payable | 4.44M | 3.30M | 4.80M | 3.70M | 5.10M | |||
| Other Current Liabilities | 0.00 | 1.90M | N/A | N/A | N/A | |||
| Total Current Liabilities | 16.73M | 17.00M | 13.20M | 8.00M | 7.90M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 18.89M | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 15.48M | 12.30M | 17.20M | 16.20M | 1.00M | |||
| Total Non-Current Liabilities | 34.38M | 34.70M | 40.60M | 38.20M | 21.70M | |||
| TOTAL LIABILITIES | 51.10M | 51.70M | 53.80M | 46.20M | 29.60M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -660.82M | -637.20M | -605.60M | -570.50M | -523.90M | |||
| Additional Paid In Capital | 695.78M | 691.80M | 694.80M | 658.20M | 606.70M | |||
| Minority Interest | 2.60M | 31.14M | 24.20M | 22.92M | 21.10M | |||
| Common Shares | 1.00K | 0.00 | 1.40M | 1.20M | 1.00M | |||
| Treasury Stock | -9.60M | -9.30M | -8.00M | -8.00M | -8.00M | |||
| Other Shareholders' Equity | -1.20M | -700.00K | 2.00M | 600.00K | -2.70M | |||
| Shares Outstanding | 13.38M | 13.50M | 14.00M | 12.40M | 9.80M | |||
| Tangible Book Value per Share | 1.67 | 3.22 | 5.16 | 5.51 | 5.72 | |||
| Total Shareholders' Equity | 24.16M | 44.60M | 84.50M | 81.50M | 73.00M | |||
| TOTAL LIABILITIES AND EQUITY | 75.27M | 96.20M | 138.30M | 127.70M | 102.60M | |||
| Statistics | ||||||||
| Debt/Equity | 0.78 | N/A | N/A | N/A | N/A | |||
| Current Ratio | 3.55 | 4.32 | 4.70 | 9.25 | 7.78 | |||
| Return On Assets (ROA) | -35.82% | -42.63% | -26.50% | -37.82% | -44.86% | |||
| Return On Equity (ROE) | -111.57% | -91.95% | -43.37% | -59.25% | -63.05% | |||
All data in USD